Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.

[1]  Yohei Imamura,et al.  Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  R. West,et al.  Diffuse High Intensity PD–L1 Staining in Thymic Epithelial Tumors , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  Roman K. Thomas,et al.  PD-L1 expression in small cell neuroendocrine carcinomas. , 2015, European journal of cancer.

[4]  J. Lunceford,et al.  Abstract CT105: MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): Antitumor activity and association with tumor PD-L1 expression , 2014 .

[5]  F. Venuta,et al.  Tumours of the thymus: a cohort study of prognostic factors from the European Society of Thoracic Surgeons database. , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[6]  Y. Nakanishi,et al.  Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  A. Bezjak,et al.  Prognostic Factors for Cure, Recurrence and Long-Term Survival After Surgical Resection of Thymoma , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  S. Strome,et al.  The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. , 2014, Oral oncology.

[9]  R. Herbst,et al.  Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC). , 2014 .

[10]  J. Lunceford,et al.  Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. , 2014 .

[11]  Yih-Leong Chang,et al.  Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. , 2014, European journal of cancer.

[12]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[13]  Vamsidhar Velcheti,et al.  In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas , 2014, Clinical Cancer Research.

[14]  T. Okazaki,et al.  A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application , 2013, Nature Immunology.

[15]  J. Feliu,et al.  Thymoma and thymic carcinoma in the target therapies era. , 2013, Cancer treatment reviews.

[16]  L. Terracciano,et al.  Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. , 2013, European journal of cancer.

[17]  Luciane T. Kagohara,et al.  PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival , 2013, Cancer Immunology Research.

[18]  Ping Yang,et al.  Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. , 2013, Clinical lung cancer.

[19]  C. Mu,et al.  Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Non-Small Cell Lung Cancer: A 5-year-follow-up Study , 2012, Tumori.

[20]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[21]  M. Okada,et al.  Steroid receptor expression in thymomas and thymic carcinomas , 2011, Cancer.

[22]  T. Okazaki,et al.  Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma , 2010, Cancer.

[23]  S. Qiu,et al.  Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma , 2009, Clinical Cancer Research.

[24]  M. Azuma,et al.  Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer , 2007, Clinical Cancer Research.

[25]  Yoshimasa Tanaka,et al.  Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[26]  R. Thompson,et al.  Implications of B7-H1 Expression in Clear Cell Carcinoma of the Kidney for Prognostication and Therapy , 2007, Clinical Cancer Research.

[27]  N. Xu,et al.  Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. , 2006, Acta histochemica.

[28]  J. Cheville,et al.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. , 2006, Cancer research.

[29]  M. Azuma,et al.  Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer , 2005, Clinical Cancer Research.

[30]  M. Nishimura,et al.  B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression , 2004, Clinical Cancer Research.

[31]  H. Müller-Hermelink,et al.  Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  R. Pfeiffer,et al.  Malignant thymoma in the United States: Demographic patterns in incidence and associations with subsequent malignancies , 2003, International journal of cancer.

[33]  G. Freeman,et al.  Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1 , 2003, The Journal of Immunology.

[34]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[35]  Y. Hayata.  16th World Conference on Lung Cancer. , 1999, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[36]  E B Cox,et al.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. , 1985, Archives of pathology & laboratory medicine.

[37]  R. Herbst,et al.  Programmed death ligand-1 expression in non-small cell lung cancer , 2014, Laboratory Investigation.